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Summary Long-circulating (stealth) liposomes coated with polyethylene glycol (PEG), which show reduced
uptake by the reticuloendothelial system (RES) and enhanced accumulation in tumours, were used for
conjugation to monoclonal antibodies (MAbs) as a drug-targeting device. A MAb (N-12A5) directed against
erbB-2 oncoprotein, a functional surface antigen, was used. Amplification and overexpression of the erbB-2
gene product, being unique to malignancy, confer onto this antibody-mediated therapy high tumour specificity.
In vitro binding of [3H]cholesteryl ether ([3H]Chol ether) labelled anti-erbB-2 conjugated liposomes to N-87 cells
(erbB-2-positive human gastric carcinoma) was compared with the binding of non-targeted liposomes and
indicated a 16-fold increase in binding for the targeted liposomes. No difference in binding to OV1063 cells
(erbB-2-negative human ovary carcinoma) was observed. These results indicate highly selective binding of
antibody-targeted liposomes to erbB-2-overexpressing cells. Despite increased cell binding, doxorubicin (DOX)
loaded in anti-erbB-2-conjugated liposomes did not cause increased in vitro cytotoxicity against N-87 cells,
suggesting lack of liposome internalisation. In vivo, the critical factor needed to decrease the non-specific RES
uptake and prolong the circulation time of antibody-conjugated liposomes is a low protein to phospholipid
ratio (<60 pg pmol-'). Using these optimised liposome preparations loaded with DOX and by monitoring the
drug levels and the [3H]Chol ether label, biodistribution studies in nude mice bearing subcutaneous implants of
N-87 tumours were carried out. No significant differences in liver and spleen uptake between antibody-
conjugated and plain liposomes were observed. Nevertheless, there was no enhancement of tumour liposome
levels over plain liposomes. Both liposome preparations considerably enhanced DOX concentration in the
tumour compared with free drug administration. Therapeutic experiments with N-87 tumour-bearing nude mice
indicated that anti-tumour activity of targeted and non-targeted liposomes was similar, although both
preparations had an increased therapeutic efficacy compared with the free drug. These studies suggest that
efficacy is dependent on drug delivery to the tumour and that the rate-limiting factor of liposome accumulation
in tumours is the liposome extravasation process, irrespective of liposome affinity or targeting to tumour cells.
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Recent advances in the design of liposomes have resulted in
the development of 'stealth liposomes', small (<100 nm)
vesicles, with prolonged circulation time and enhanced tumour
localisation properties (Papahadjopoulos et al., 1991). These
liposomes localise in the tumour extracellular compartment
but are not taken up by tumour cells (Gabizon, 1992; Huang
et al., 1991; Papahadjopoulos et al., 1991). To enhance
cytotoxic efficacy further, selective delivery of drugs to target
cells can be achieved through liposome binding of antibodies
that recognize specific determinants on target cells (Ahmad
and Allen, 1992; Debs et al., 1987; Peeters et al., 1989). The c-
erbB-2 gene product is a membrane glycoprotein of 185 kDa
(pl85HER2) with intrinsic kinase activity. As the product of an
activated oncogene, erbB-2 represents an important class of
tumour-surface antigens for diagnosis or targeting of
monoclonal antibody-mediated therapy (Harris and Mas-
trangelo, 1989). Amplification and overexpression of the c-
erbB-2 gene is shown in many epithelial malignancies,
particularly in breast and ovarian carcinomas (15-20% of
human carcinomas) (Berchuck et al., 1990; Yonemura et al.,
1991), predicting a poor prognosis (Slamon et al., 1987, 1989;
Park et al., 1992). The phenomenon is unique to malignancy.
In normal tissues p185HER2 is expressed only at low levels in
certain epithelial cell types (Press et al., 1990). As the
oncoprotein plays a role in cell growth and oncogenesis,
blocking it by antibodies may interfere with signal transduc-
tion pathways. Moreover, being a membranous overexpressed
antigen with ready accessibility and high level of tumour
specificity, erbB-2 offers an attractive target for cancer
therapy. Here, we describe the development of anti-erbB-2
immunoliposomes as a tumour-targeting vehicle in which the
specificity of anti-p185HER2 and the cytotoxic activity of DOX
are combined with the pharmacokinetic and drug delivery
advantages of liposomes. N12A5 (IgGI) MAb, which has a
high binding capacity to erbB-2-overexpressing cells (Stan-
covski et al., 1991), was selected for our studies of targeted
therapy with doxorubicin-loaded 'stealth liposomes'. N12A5
significantly inhibited the tumour growth ofhuman carcinoma
cell line N-87 and mouse fibroblasts transfected with the
human gene in nude mice (Hurwitz et al., 1995), and
specifically induced phenotypic differentiation on various
cultured breast carcinoma lines (Bacus et al., 1992). The
erbB-2-positive human gastric carcinoma line N-87 (Park et
al., 1990), which grows well in nude mice, was chosen as
tumour model.
Materials and methods
Liposome preparation
Sources of liposome components were as follows: hydro-
genated soybean phosphatidylcholine (HPC) was from
Avanti Polar Lipids (Birmingham, AL, USA); cholesterol
(Chol) and ac-tocopherol were from Sigma (St Louis, MO,
USA); mPEG(2000)/DSPE (polyethylene glycol derivative of
distearoylphosphatidyl ethanolamine) and Hz-PEG-DSPE
were prepared as described elsewhere (Zalipsky, 1993a); and
[3H]cholesteryl hexadecyl ether was from NEN (Boston, MA,
USA). Stealth liposomes (HPC-mPEG DSPE-Chol-Hz-
PEG-DSPE-a-Tocopherol; 92.5: 5:70:2.5:1 molar ratio)
and trace amount of [3H]Chol ether (150 pCi per 500 pmol
phospholipid) were prepared as described by Papahadjopou-
los et al. (1991). The DOX phospholipid ratio obtained was
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50-80 jug Mmolh-' and vesicle size 70+20 nm. A liposomal
DOX preparation of similar composition but lacking the Hz-
PEG derivative, known as Doxil, was provided by Sequus
(Menlo Park, CA, USA).
Immunoliposome preparation
Ascitic fluid from mouse hybridomas producing monoclonal
oc-erbB-2 antibodies Nl2A5 (Stancovski et al., 1991) was
supplied by Dr Yarden (Weizmann Institute, Israel). Isolation
of MAb was done using a protein A -Sepharose column
(Sigma). Conjugation was carried out via hydrazone linkage
of the liposome hydrazide moiety with oxidised carbohy-
drates on the Fc portion of the oc-erbB-2 antibodies (Allen et
al., 1994; Zalipsky et al., 1993b). Sodium periodate (10 mM)
was used for oxidation of carbohydrates. Unreacted period-
ate was quenched with excess N-acetylmethionine (NAM)
(50 mM). Quick reduction in the amount of NAM
commensurate with the amount of periodate present,
presumably by conversion into methionine sulphoxide and
sulphone derivatives, as confirmed by HPLC (Zalipsky,
unpublished results). For the coupling reaction, anti-erbB-2
antibodies (3-5 mg ml-') and stealth liposomes (30-
50 ,umol phospholipid ml-1) were co-incubated overnight at
room temperature, in 0.1 M acetate buffer pH 5.5, at a molar
ratio of 1: 200 MAb-Hz-PEG-DSPE to attain 40-60 Mg
IgG Mmol` phospholipid. Uncoupled antibody was sepa-
rated from immunoliposomes by gel filtration with the Bio-
Rad, Agarose Bio-Gel A-15m. Determination of conjugation
level was done by the Pierce Coomassie Protein Assay
Reagent (Pierce, Rockford, IL, USA). The stability of the
hydrazone bond conjugating the antibody to Hz-PEG has
been examined and proven in vivo (Zalipsky et al., 1995).
Cell lines
We chose a human-derived gastric carcinoma, N-87,
described previously by Park et al. (1990), with the ability
to develop tumours in nude mice and breast carcinoma BT-
474, both with c-erbB-2 overexpression. ZR-75.1 and OV1063
(Horowitz et al., 1985) breast and ovary human carcinoma
lines with low expression of erbB-2 were used as control cells.
Binding in vitro
Binding was assayed through measurement of cell-associated
liposomal [3H]Chol ether. Approximately 5 x 105 N-87 cells in
RPMI + 10% fetal calfserum (FCS) were grown in 35 mm dish
for 72 h; the medium was then replaced by medium containing
liposomes (200 nmol phospholipid/per dish) for the indicated
periods. Extraction of [3H]chol ether and DOX from
phosphate-buffered saline (PBS)-washed N-87 cells was
accomplished using 0.075 N hydrochloric acid in 90%
isopropanol at 4°C overnight. Non-specific association of
liposomes was measured by the use ofempty culture dishes as a
control. The counts of these control dishes were subtracted.
Cytotoxicity in vitro
N-87 cells seeded at a density of 5 x 103 per well (96-well
plate) were incubated in RPMI + 10% FCS for 3 days in the
presence of liposomal and free DOX (10-' to 10' M)
without change of medium. In one of the experiments, cells
were exposed to the drug for 2 h, the medium was then
replaced and the cells incubated for 3 days. Cell growth was
assayed colorimetrically by methylene blue staining. A
detailed description of the in vitro cytotoxicity test has been
reported previously (Horowitz et al., 1992).
Biodistribution studies
Biodistribution of plain and immuno stealth liposomes
injected i.v. into tumour-bearing nude mice was examined.
N-87 cells (6 x 106) were s.c. injected into both flanks of
athymic nude balb/c female mice. Fourteen days after
inoculation, when the average tumour weight was
- 100 mg, the mice were injected i.v. with 10 mg kg-'
DOX (2-4 ,mol phospholipid per mouse). Doxorubicin
was given as free drug, in plain liposomes and in
immunoliposomes. At 1, 4, 24, 48 and 96 h after the
injection, the animals were anaesthesised with ether inhala-
tion, bled by eye enucleation and immediately sacrificed for
removal of tumours, skin and liver. Each group consisted of
five mice. Liposomal tracers were [3H]Chol ether, a non-
degradable fl-emitter with very stable association to liposome
bilayers, and DOX, which serves as a liposome inner water
compartment marker, assayed by HPLC with a fluorometric
detector. The extraction procedure consisted of homogenisa-
tion of -200 mg wet tissue in 1.8 ml double-distilled water
supplemented with 0.5 Mug daunorubicin (Roger Bellon,
France) as internal standard and 33% silver nitrate to help
detach the DNA-bound drug, followed by centrifugation,
removal of pellet and addition to the supernatant of
chloroform-isopropanol (2 ml of each solvent) and 1.5 g
ammonium sulphate. Phase separation, for the collection of
lipids and DOX in the chloroformic upper phase, was done
by vortexing and 20 min centrifugation at 10 000 r.p.m.
Because of the high concentration of ammonium sulphate,
the water phase density increases above that of the organic
phase, which then becomes the upper phase. The high ionic
strength of the water phase is also necessary to force DOX
into the organic phase and increase the efficiency of
extraction. The volume of the upper phase was measured
and 500 ,l was monitored for [3H]Chol ether presence using a
fl-counter. For DOX quantification the remaining upper
phase was evaporated to dryness and redissolved in 35%
HPLC-grade acetonitrile (Lab Scan Analytical Sciences,
Dublin, Eire) and 65% double-distilled water. HPLC
analysis of DOX proceeded by filtration of the samples
through 0.2 gm filters, followed by centrifugation and
examination of the clear supernatants by injection into an
isocratic HPLC system with a reverse-phase C8 column, and
fluorescence detection using a Kontron-SFM 25 Spectro-
fluorometer (Kontron Instruments, Zurich, Switzerland). For
DOX quantification, an excitation wavelength of 470 nm and
an emission wavelength of 590 nm were used. The mobile
phase composition was: 35% acetonitrile, 65% double-
distilled water and 0.001% desipramine (Sigma), pH 2.5
(HCl), with a flow rate of 2 ml min-'. Helium degasing was
carried out before each run.
The amount of [3H]Chol ether in plasma was determined
directly by fl-counting of the plasma sample, and the
amount of DOX was determined by an extraction
procedure similar to that described for organs. Daunor-
ubicin (20 Ml) was spiked into each 400 Ml sample: 1.0 Mg for
plasma samples after 48 h and 5.0 Mg for plasma samples up
to 48 h, as internal standard. A 400 Ml aliquot plasma
sample, 400 Ml isopropyl alcohol (HPLC grade), 400 Ml of
chloroform (HPLC grade) and 500 mg of ammonium
sulphate (Sigma) were mixed, vortexed and centrifuged to
achieve phase separation and isolation of lipids and DOX in
the organic upper phase. The chloroformic upper phase was
dried, redissolved in 400 Ml of HPLC mobile phase, filtered
through 0.2 Mm-pore polycarbonate filters and injected into
the HPLC system described above.
In all cases, the biodistribution results were expressed as
per cent injected dose per gram tissue (%ID g-'). [3H]Chol
ether c.p.m. were measured in a scintillation counter and
translated into %ID g-1. The fluorescence intensity peak of
DOX obtained by HPLC was converted into Mug g-', based
on the daunorubicin internal standard. These values were
also converted into %ID g-1.
Therapeutic studies
Each mouse was injected with two inocula of tumour cells
(5 x 106 N-87 cells) subcutaneously into each flank. Intrave-
nous treatment was given 15 days after inoculation. The twoUposome targeting to erbB-2-positive cells
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largest perpendicular diameters of the palpable tumours were
measured using calipers, starting on the first treatment day
and three times a week thereafter. Tumour volume and
approximate weight were estimated by the equation ab2/2
(in mm3 or mg), where a and b are the two largest
perpendicular diameters. The tumour volume/weight values
were converted in percent change from baseline by the
equation V, x 100/Vo, where V1 is volume measured at time
t and V0 is baseline volume. Mice were labelled individually
for individual follow-up of tumour growth and tumour
weight. Two months after start of treatment, all surviving
mice were sacrificed and tumours were dissected carefully and
weighed directly.
Results
In vitro binding of immunoliposomes andplain stealth
liposomes to erbB-2-positive and -negative cells
The binding kinetics of antibody-targeted liposomes and non-
targeted liposomes to N-87 cells, erbB-2 overexpressors were
studied for 24 h (Figure 1). Cell association of liposomes
([3H]Chol ether) and DOX was monitored as described. The
binding kinetics curves show that at least 2 h is needed for a
measurableassociation to occur. Therewasmore thana 10-fold
increase inliposome bindingwhen antibody was conjugated, as
indicated by the [3H]Chol ether marker (Figure la). When
DOX was measured, the maximum increase in cell association
using antibody-targeted liposomes was 5-fold after 8 h of
incubation (Figure Ib). After 24 h ofincubation, this increased
factor of DOX cell association went down to 2.5-fold which
was probably a result of the masking effect of DOX leakage
from liposomes on the targeting effect. Drug leakage studies
from plain liposomes andimmunoliposomes, in the presence of
90% plasma at 37°C, did not reveal any significant differencein
stability between plain liposomes and immunoliposomes (data
not shown). In the following in vitro binding experiments,
attachment was monitored after 7 h incubation of liposomes
with cells.
Binding of plain, irrelevant Ab or anti-erbB-2 (N12A5)
MAb-conjugated liposomes to erbB-2-positive N-87 cells
(106) was examined after 7 h incubation at 37°C with
200 nmol of phospholipid per plate (35 mm). Figure 2
demonstrates a 16-fold increase in a-erbB-2 liposome
association to N-87 cells compared with the attachment of
plain liposomes or liposomes conjugated to polyclonal
(irrelevant) IgG. This experiment was done with similar
levels of Ab coupled to liposomes, i.e. 52 and 58 Mg pmol-1
phospholipid of relevant and irrelevant Ab respectively.
Attachment of non-targeted and a-erbB-2-targeted stealth
liposomes to N-87 and OV-1063 cells, erbB-2-positive and
negative respectively. A 19-fold increase in [3H]Chol ether
association to N-87 (erbB-2-positive) cells, compared with
OV-1063 (erbB-2-negative) cells, when co-incubated with
anti-erbB-2 immunoliposomes was obtained, as shown in
Figure 3. These results, together with our previous results,
confirm the specific and avid targeting conferred by anti-
erbB-2 IgG coupling to liposomes through PEG-hydrazide.
In additional experiments with the breast carcinoma line BT-
474 (erbB-2-positive) we observed the same net increase in
specific binding of a-erbB-2-targeted liposomes - 1.5-
2.0 nmol phospholipid/106 cells - similar to that obtained
with N-87 cells under the same experimental conditions (data
not shown).
In vitro cytotoxicity of immunoliposome- and plain liposome-
DOX on N-87 cells
In vitro cytotoxicity studies of the soluble anti-erbB-2 MAb
(N12A5) on erbB-2-positive cells revealed that there was a
maximum of 20% growth inhibition of N-87 cells (erbB-2-
positive) without affecting the growth of OV-1063 cells (erbB-
2-negative). A control polyclonal IgG did not cause growth
inhibition. When N-87 cells were exposed to N12A5 antibody
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Figure 1 Binding kinetics of immunoliposomes (conjugated to x-
erbB-2 MAb) and plain liposomes to erbB-2-positive cells, at
37°C for 24h. N-87 cells were seeded at a density of 106/plate
(35mm). Each time point is the mean of five replicates. s.d. did
not exceed+5%. 0, plain liposomes; 0, immunoliposomes.
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Figure 2 Binding of immunoliposomes and control liposomes to
erbB-2-positive cells: liposome binding was carried out at 37°C
for 7h. Phospholipid concentration, 200 nmolml -'; protein/
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Figure 3 Binding of immunoliposomes to human carcinoma
cells, erbB-2-positive (N-87) and negative (OV-1063). Binding was
carried out with 200nmol phospholipidml- , at 37°C for 7h.
Protein/phospholipid ratio, 52jug IgGjumol-1. *, N-87; EL, OV-
1063. Each bar is the mean of five replicates.
and free DOX or liposomal DOX, we found a simple additive
effect with no evidence of synergistic inhibition of growth
(data not shown). Comparison of the cytotoxic activity of
liposomal (immuno and plain) with free DOX on N-87 cells,
presented in Figure 4, showed no difference between a-erbB-
2-coupled liposomes and plain liposomes. IC50 values for
plain liposome and immunoliposome DOX were
1.3 x 10-6 M, while the soluble drug was 6-fold more active
(2.1 x 10-7 M). In another design of the cytotoxic experiment,
N-87 cells were incubated for only 2 h in the presence of
DOX (liposomal or free) and then further incubated for 3
days in fresh medium (Figure 4). IC50 values for plain and
immunoliposomes were similar (1.3 x 10' M) and higher
than for the free drug by
- 10-fold (1.1 x 10-6 M).
Consistent with this, experiments with BT-474 also demon-
strate insignificant differences in IC50 values of DOX in
immunoliposomes and plain liposomes (1.1 X 10-6 M and
1.5 x 10-6 M respectively). These results corroborate previous
observations indicating that cytotoxicity originates from
liposomal drug release in the extracellular fluid and free
drug diffusion into the cells (Horowitz et al., 1992). In the
following experiments, we focused on the N-87 cell line, as
this tumour is a very reliable and convenient model for in
vivo therapeutic studies (Hurwitz et al., 1995).
3 days incubation
-cO- F-DOX
--- Immunoliposome DOX
0- Plain liposome DOX
DOX (nM)
Figure 4 Cytotoxic effect of DOX in immunoliposomes and
plain liposomes on N-87 cells. Approximately 5 x 103 cells per
well (96-well plate) were seeded. Twenty-four hours later the cells
were exposed to liposomal and free DOX (10-7 to 10-5M) for
2h. After exposure to the drug, the cells were washed and
incubated in RPMI medium for another 3 days. In a second
experiment, the cells were incubated for 3 days in the presence of
liposomal and free DOX. Cell growth was assayed by methylene
blue staining. Each point is the mean of six replicates, and the
standard deviation did not exceed+ 10%. IC50 values for
liposomal DOX (immuno and plain) and for free DOX were
1.3 x 10-5M and 1.1 x 10-6M respectively after 2h of incubation
and 1.3 X 10-6M and 2.1 X 10-7M respectively after 3 days of
incubation.
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Biodistribution studies
Plasma (Figure 5) Initial pharmacokinetic experiments of
antibody-targeted liposomes in mice were done with a-erbB-2-
conjugated liposome preparations of relatively high protein/
phospholipid ratio, around 100 jug umol-'. As shown in Figure
5a, high-protein immunoliposomes were cleared from plasma
significantly faster than plain liposomes and low-protein
immunoliposomes (44 ug ymol-'). As shown in Figure Sb,
the differences in plasma DOX clearance rates between targeted
and non-targeted liposomes were minimal when a liposome
preparation with low protein to lipid ratio was used. DOX and
[3H]Chol ether showed a similar clearance rate, suggesting that
drug leakage is a minor pathway ofclearance. We inferred that
low levels of protein conjugated to liposomes are required to
maintain stealth qualities of immunoliposomes. Further
experiments, shown below, were carried out with these low-
protein immunoliposomes.
Liver (Figure 6a) There was no increased liver uptake of
immunoliposomes compared with plain liposomes, as
reflected in the [3H]Chol ether levels. When the DOX liver
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Figure 5 Plasma clearance of immunoliposomes and plain
liposomes injected i.v. into nude mice bearing s.c. implanted N-
87 tumours. (a) Phospholipid dose, 2-4,mol per mouse. (b)
DOX dose, 10mgkg . *, plain liposomes; A, immunolipo-
somes (protein/phospholipid ratio 44 igjmol-1); A, immunolipo-
somes (protein/phospholipid ratio 100ugpmol-1). The plasma
levels ofDOX, in mice injected with the free drug, were negligible.
Each group consisted of five mice.
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r-nlevels were examined, the peak levels were similar, but it
appeared that the drug clearance with immunoliposomes was
faster than with plain liposomes. This suggests that
immunoliposomes may be incorporated faster than plain
liposomes into an intracellular compartment where liposome
degradation and drug release occur. Liver uptake was not
enhanced when immunoliposomes with low protein to lipid
ratio were used.
Tumour (Figure 6b) Liposome levels in the tumour implants
were slightly higher for plain liposomes than for immunolipo-
somes when either DOX or [3H]Chol ether is considered. It
should be noted that the levels of [3H]Chol ether did not show
any significant decrease even as late as 4 days after injection.
The reason forthis is that [3H]Chol etheris in anon-degradable
form (ether-bond) and therefore the [3H]Chol ether values
indicate a cumulative liposome localisation in tissues. It is clear
from Figure 6b that the tumour drug levels are much higher
when DOX is delivered by plain-liposomes or immunolipo-
somes than free DOX, indicating a substantial advantage of
liposome delivery with respect to tumour drug exposure.
Skin (Figure 6c) In the skin, high levels of liposomes were
detected. Liposome distribution in skin represents the largest
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depot of liposomes in the nude mouse. As the total skin
weight in a mouse is about 3 g (twice that of the liver), an
uptake of 10% ID g-1 indicates that about 30% of the
injected liposomes accumulated in skin.
Therapeutic study
As pharmacokinetic studies have shown a close pattern of in
vivo distribution for the plain and immunoliposomes, we
proceeded by examining whether antibody targeting to
tumour cells would result in enhanced therapeutic efficacy
of immunoliposomes. Nude mice bearing subcutaneously
implanted N-87 carcinoma were treated (i.v.) with 8 mg kg-1
free and liposomal (plain and immuno) DOX on days 15 and
22 after tumour implantation, i.e. at a time when tumour
implants became palpable. The therapeutic results given in
Table I are the final median tumour weights, after sacrificing
the mice 2 months after start of treatment. There was a
significant and unequivocally greater tumour-inhibitory effect
of liposome-delivered DOX than of free DOX. However,
there was no apparent difference in tumour weight when
immunoliposome- and plain liposome-treated groups were
compared. Figure 7 summarises the relative changes in
estimated tumour volume during 60 days of follow-up. As
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Figure 6 Biodistribution of immunoliposomes and plain liposomes injected i.v. into tumour-bearing nude mice. (a) Liver
accumulation. (b) Tumour accumulation. (c) Skin accumulation. N-87 cells (6 x 106) were s.c. injected into both flanks of nude mice.
On day 14 the mice were i.v. injected with 10mgkg-1 DOX. *, free dox; *, DOX in plain liposomes; A, DOX in
immunoliposomes (protein/phospholipid ratio 44,pg ,mol-1). Each group consisted of five mice. Left, [3H]cholesterol; right, DOX
levels.
c
._
0)
*0
0
0a
.)
0)
0 ._
)O
I II I
n
--L
^ ,%
u
11
_ ,~~~~~~~~~~~~~~~~~~~~e
L ML-
.... I... 1.11 ... 11-Liposome targeting to erbB-2-positive cells
D Goren et al
Table I Tumour weights (mg) on day of sacrifice-75 days after inoculationa
Untreated control Free DOX Plain liposome-DOX Immunoliposome-DOX DoxiP
Median 1649 787 229 249 62
95% CI 581 -3990 454-1142 59-795 146-427 11-410
aOn day ofsacrifice the number ofsurviving mice was: control, 6/6; plain liposome-DOX, 6/18; immunoliposome-DOX, 8/9; free DOX, 13/14;
doxil, 5/5. bResults from a separateexperiment. Although themedianweight wasforDoxilgroup lowerthan forotherliposome-treated groups, the
relative changein tumourvolume was notsignificantly different from otherliposome-DOX groups. Statisticalanalysis(Wilcoxontest): free DOX vs
control, 0.02P<0.05; plain liposome DOX vs free DOX, 0.002<P<0.005; immunoliposome DOX vs free DOX, P<0.001.
seen in Figure 7, tumour growth was clearly slowed by
treatment, more by liposome-delivered drug than by free
drug. Groups treated with plain liposomes and immunolipo-
somes behaved similarly, plain liposomes being slightly more
effective. Addition of unconjugated, soluble antibody to free
DOX or plain liposomes, at doses equal to the amount of
antibody given with immunoliposomes (- 100 jug MAb per
mouse), did not have any impact on the therapeutic effect
(data not shown). Thus, antibody targeting of liposomes did
not endow any therapeutic advantage over plain liposomes,
nor was there a significant loss of activity.
peutic experiment, a significant number of toxic deaths
were observed in the group of animals treated with DOX
in non-targeted liposomes (12/18 mice died), in contrast to
the other experimental groups (1/9 for DOX in immuno-
liposomes, 1/14 for free DOX, 0/6 for control untreated).
All deaths occurred 3-5 weeks after the start of treatment
and were preceded by severe weight loss. An additional
group of six mice treated with DOX in liposomes lacking
the PEG-hydrazide linker (Doxil) showed no signs of
toxicity (0/6 deaths) and a level of anti-tumour activity at
least as potent as that of the PEG-hydrazide-containing
preparation (Table I). This is consistent with our past
experience (Gabizon, 1992; Papahadjopoulos et al., 1991),
which indicates that the dosage of liposomal DOX used in
this study is not toxic. These observations suggest that the
PEG-hydrazide group in unquenched form (i.e. not protein
bound) contributes to the toxicity observed, but not to the
anti-tumour activity.
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Figure 7 Therapeutic efficacy of liposomal and free DOX on s.c.
implanted N-87 tumours. Approximately 6 x 106 cells were
injected into both flanks of nude mice. On days 15 (tumour
volume of 300+ 150mg) and 22, i.v. treatment of 8mgkg-l DOX
was given as free or liposomal drug. Control is the non-treated
group. Tumour volume was measured three times a week and
estimated by the following equation ab2/2, where a is the largest
tumour diameter and b is the perpendicular diameter. *, plain
liposome DOX; A, immunoliposome DOX; 0, free DOX; O,
control. Each group consisted of at least 12 tumours. Protein/
phospholipid ratio, 52pg mol-1. Addition of free antibody, at
the same dose as the conjugated antibody (- 100Mg per mouse) to
DOX (free or liposomal), had no effect on tumour growth (data
not shown).
Discussion
Recent reports have indicated the feasibility of using
immunoliposomes for targeted drug delivery to augment the
therapeutic efficacy of an encapsulated anti-cancer drug
(Ahmad et al., 1993; Emanuel et al., 1996). These models
used DOX in Ab-targeted stealth liposomes, but their
relevance to humans is limited as they are based on mouse
tumours. We have tried to examine the likelihood that such a
strategy could succeed in a human tumour model by
targeting liposomes to erbB-2 oncoprotein, a receptor that
is stably overexpressed by certain carcinomas and required
for the maintenance of aggressive tumour growth (Berchuck
et al., 1990, Slamon et al., 1987, 1989). Our aim was to
develop stealth immunoliposomes equipped with anti-erbB-2
monoclonal antibodies, to preserve the pharmacokinetic
properties of stealth liposomes and to improve tumour drug
delivery and anti-tumour activity.
In this study, anti-erbB-2 MAb coupled to stealth
liposomes using the Hz-PEG-DSPE linker was found to
function as a specific and efficient targeting device in in vitro
systems. This is in agreement with other studies using the
same coupling system with a different antibody (Allen et al.,
1994; Zalipsky et al., 1993b).
Experiments in biodistribution studies using nude mice
bearing N-87 xenografts revealed that, despite optimal
preparation of antibody-conjugated liposomes with high in
vitro affinity to tumour cells and reduced RES uptake, no
benefit of tumour liposome levels over plain stealth liposomes
was noted.
Therapeutic experiments correlated with biodistribution
studies, i.e. similar anti-tumour efficacy of the two liposomal
preparations was found. Despite the in vitro pronounced
binding affinity of immunoliposomes to target cells, no
improvement in therapeutic efficacy was achieved.
Baselga et al. (1996), in a phase II trial using humanised
anti-erbB-2 MAbs, observed accelerated plasma clearance in
patients with high plasma levels of extracellular domain of
erbB-2 (ECDHER2). Our studies detected minimal differences
in plasma clearance rates between immunoliposomes and
plain liposomes. Whether this is the outcome of low plasma
levels of ECDHER2 or of their minor effect on circulating a-
erbB-2-targeted liposomes remains to be clarified.
Skin liposome uptake was extremely high for both
liposome preparations, a finding consistent with the skin
toxicity of a stealth liposomal DOX (Doxil) preparation in
humans (Uziely et al., 1995). High liposome localisation in
skin has been reported previously in nude mice (Gabizon et
al., 1990; Huang et al., 1993), although the underlying
mechanism remains poorly understood.
These studies suggest that the rate-limiting factor of
liposome accumulation in tumours is the liposome extravasa-
tion process, irrespective of liposome affinity or targeting to
tumour cells. This hypothesis has the following rational basis.
It is clear that the erbB-2-targeted antigens are to be found
beyond the endothelial cell barrier. Liposomes need firstly to
extravasate in tumour areas and, only then, does binding to
tumour cell receptors occur. As the extravasation efficiency of
.RLiposome targeting to erbB-2-positive cells
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plain liposomes should not be less than that of immunolipo-
somes, a difference in tumour accumulation can only be
established if the former are washed out from the tumour
area faster than the latter. However, given the relatively large
size of liposomes and the lack of functional lymphatic
drainage in tumours (Jain, 1989) it is likely that most
extravasated vesicles will remain in the tumour site, whether
cellbound or not, until they are degraded or cleared by
scavenger cells. For complexes of smaller size than liposomes,
for which return to the circulation is feasible, binding to an
extravascular target cell will be an important determinant of
tumour accumulation through decreased washout from the
tumour. In fact, a number of soluble MAbs do show a
selective enhancement of concentration in the targeted
tumour in comparison with irrelevant MAb (Jakowatz et
al., 1985). In line with this, enhanced in vivo efficacy of
N12A5 MAb against N-87 tumour (Hurwitz et al., 1995), and
of other anti-erbB-2 antibodies in various tumour models
(Bacus et al., 1992; Harwerth et al., 1993), has been obtained.
A recent report (Park et al., 1995) of a study with Fab'
fragments of anti-erbB-2 MAb (from a different source)
conjugated via MPB-PE to the lipid bilayer of stealth
liposomes demonstrates internalisation of immunoliposomes
by human-derived breast carcinoma cells (SKBR3, erbB-2-
positive) in vitro and augmented cytotoxicity of anti-erbB-2-
targeted liposomes over plain liposomes. Unfortunately, the
N-87 model did not show an increased in vitro sensitivity to
immunoliposomes, suggesting lack of internalisation of the
cell-bound immunoliposomes into the target cells, or
liposomal drug localisation in a non-bioavailable cellular
compartment. It should be noted that soluble anti-erbB-2
N12A5 MAb is internalised by N-87 cells in vitro to a great
extent (85%) as shown by Hurwitz et al. (1995). These
observations indicate differences in internalisation capacity
among the various erbB-2-positive carcinoma cell-lines, or an
advantage for Fab' fragments over the bulkier whole IgG in
facilitating internalisation. A third possibility is that the
lower molar fraction of PEG in the liposomes used by Park
et al. (1995) (2% PEG of total phospholipid) may have
facilitated internalisation compared with the liposomes used
here (7.5% PEG). However, even in the presence of 6.7%
PEG, internalisation of liposomes is still possible, as
demonstrated by Lee and Low, (1995), with folate-targeted
stealth liposomes and cell lines overexpressing folic acid
receptor. These authors also reported that internalisation was
accompanied by an increase in the cytotoxicity of liposomal
DOX. Whether as a result of the intrinsic properties of the
target cells and their receptors, the density of the liposome
PEG coating, or the nature and size of the ligand,
internalisation may be a necessary step to enhance the
cytotoxicity of DOX encapsulated in targeted liposomes, and
hence translate targeting into enhanced efficacy. The
argument for internalisation in vivo would be that drug
released in the tumour intracellular compartment cannot
escape from the tumour, while drug released in the interstitial
fluid, as in the case of non-targeted liposomes, may still be
partially washed out from the tumour and return to
circulation.
A positive result of the therapeutic study was the enhanced
efficacy of stealth liposomal DOX, with or without targeting
antibodies, over free DOX. Similar observations have been
made in a number of human xenograft models (Williams et
al., 1993; Vaage et al., 1994). As emphasised in this study, the
factors involved in the design of immunoliposomes are
complex and unique to this system, and the results may not
be extrapolatable to other tumour models, particularly in
cases in which the drug becomes bioavailable in the
intracellular compartment as a result of immunoliposome
internalisation. Our results highlight the serious limitations of
the antibody-liposome targeting approach to extravascular
tumours. Nevertheless, the advantages of the liposome
approach [multivalent binding and delivery of a large drug
payload; the availability of long-circulating liposomes; an
ever-increasing variety of ligand-coupling techniques; and the
possibility of aiming at alternative targets such as the tumour
microvasculature (Burrows and Thorpe, 1993) or intravas-
cular targets] justify further investigation in this field.
Abbreviations
DOX, doxorubicin; Chol, cholesterol; [3H]Chol ether,
[3H]cholesteryl hexadecyl ether; mPEG, polyethylene glycol; Hz,
hydrazide; DSPE, distearoyl phosphatidylethanolamine; MPB-PE,
maleimidophenylbutyryl phosphatidylethanolamine; NAM, N-
acetylmethionine, a-Toco, a-tocopherol.
Acknowledgements
We are grateful to Dr Esther Hurwitz for helpful advice in the
purification of antibodies, and to Dina Tzemach for technical help.
Work supported by the Israel Ministry of Science and Technology
and by Sequeus Pharmaceuticals (Menlo Pk., CA, USA).
References
AHMAD I AND ALLEN TM. (1992). Antibody-mediated specific
binding and cytotoxicity of liposome entrapped doxorubicin to
lung cancer cells in vitro. Cancer Res., 52, 4817-4820.
AHMAD I, LONGENECKER M, SAMUEL J AND ALLEN TM. (1993).
Antibody-targeted delivery ofdoxorubicin entrapped in sterically
stabilized liposomes can eradicate lung cancer in mice. Cancer
Res., 53, 1484- 1488.
ALLEN TM, AGRAWAL AK, AHMAD I, HANSEN CB AND ZALIPSKY
S. (1994). Antibody-mediated targeting of long circulating
(Stealth) liposomes. J. Liposome Res., 4, 1 -25.
BACUS SS, STANCOVSKI I, HUBERMAN E, CHIN D, HURWITZ E,
MILLS GB, ULLRICH A, SELA M AND YARDEN Y. (1992). Tumor
inhibitory monoclonal antibodies to the HER-2/neu receptor,
induce differentiation of human breast cancer cells. Cancer Res.,
52, 2580-2589.
BASELGA J, TRIPATHY D, MENDELSOHN J, BOUGHMAN S, BENZ
CC, DANTIS L, SKLARIN NT, SEIDMAN AD, HUDIS CA, MOORE
J, ROSEN PP, TWADDELL T, HENDERSON C AND NORTON L.
(1996). Phase II study of weekly intravenous recombinant
humanized anti-pl85HE 2 monoclonal antibody in patients with
HER2/neu-overexpressing metastatic breast cancer. J. Clin.
Oncol., 14, 737-744.
BERCHUCK A, KAMEL A, WHITAKER R, KERNS B, OLT G, KINNEY
R, SOPER JT, DODGE R, CLARKE-PEARSON DL AND MARKS P.
(1990). Overexpression of HER-2/neu is associated with poor
survival in advanced epithelial ovarian cancer. Cancer Res., 50,
4087-4091.
BURROWS FJ AND THORPE PE. (1993). Eradication of large solid
tumors in mice with an immunotoxin directed against tumor
vasculature. Proc. Natl Acad. Sci. USA, 90, 8996-9000.
DEBS RJ, HEATH TDAND PAPAHADJOPOULOS D. (1987). Targeting
of anti-thy 1.1 monoclonal antibody- conjugated liposomes in
Thy 1.1 mice after intravenous administration. Biochim. Biophys.
Acta, 901, 183- 190.
EMANUEL N, KEDAR E, BOLOTIN EM, SMORODINSKY NI AND
BARENHOLZ Y. (1996). Targeted delivery of doxorubicin via
sterically stabilized immunoliposomes: pharmacokinetics and
biodistribution in tumor-bearing mice. Pharm. Res., 13, 861 -868.
GABIZON A. (1992). Selective tumor localization and improved
therapeutic index of anthracyclines encapsulated in long
circulating liposomes. Cancer Res., 52, 891 -896.
GABIZON A, PRICE DC, HUBERTY J, BRESALIER RS AND
PAPAHADJOPOULOS D. (1990). Effect of liposome composition
and other factors on the targeting of liposomes to experimental
tumors: biodistribution and imaging studies. Cancer Res., 50,
6371 -6378.
HARRIS DT AND MASTRANGELO MJ. (1989). Serotherapy of
cancer. Semin. Oncol., 16, 180-198.
HARWERTH IM, WELS W, SCHLEGEL J, MUELLER M AND HYNES
NE. (1993). Monoclonal antibodies directed to the erB-2 receptor
inhibit in vivo tumour cell growth. Br. J. Cancer, 68, 1140- 11450-"- Liposome targeting to erbB-2-positive cells
1756 D Goren et al
1756
HOROWITZ AT, TREVES AJ, VOSS R, OKON E, FUKS Z, DAVIDSON L
AND BIRAN S. (1985). A new human ovarian carcinoma cell line:
establishment and analysis of tumor-associated markers. Oncol-
ogy, 42, 332- 337.
HOROWITZ AT, BARENHOLZ Y AND GABIZON A. (1992). In vitro
cytotoxicity of liposome-encapsulated doxorubicin: dependence
on liposome composition and drug release. Biochim. Biophys.
Acta, 1109, 203-209.
HUANG SK, HONG K, LEE KD, PAPAHADJOPOULOS D AND
FRIEND DS. (1991). Light microscopic localization of silver
enhanced liposome entrapped colloidal gold in mouse tissues.
Biochim. Biophys. Acta, 1069, 117-121.
HUANG SK, MARTIN FJ, JAY G, VOGEL J, PAPAHADJOPOULOS D
AND FRIEND DS. (1993). Extravasation and transcytosis of
liposomes in Kaposi's sarcoma-like dermal lesions of transgenic
mice bearing the HIV tat gene. Am. J. Pathol., 143, 10- 14.
HURWITZ E, STANCOVSKI I, SELA M AND YARDEN Y. (1995).
Suppression and promotion of tumor growth by monoclonal
antibodies to ErbB-2 differentially correlate with cellular uptake.
Proc. Natl Acad. Sci. USA, 92, 3353-3357.
JAIN RK. (1989). Delivery of novel therapeutic agents in tumors:
physiological barriers and strategies. J. Natl Cancer Inst., 81,
570- 576.
JAKOWATZ GJ, BEATTY BG, VLAHOS WG, PORUDOMINSKY D,
PHILBEN VJ, WILLIAMS LE, PAXTON RJ, SHIVLEY JE AND
BEATTY JD. (1985). High-specific-activity 'In-labeled antic-
arcinoembryonic antigen monoclonal antibody: biodistribution
and imaging in nude mice bearing human colon cancer
xenografts. Cancer Res., 45, 5700- 5706.
LEE RJ AND LOW PS. (1995). Folate-mediated tumor cell targeting of
liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta,
1233, 134- 144.
PAPAHADJOPOULOS D, ALLEN TM, GABIZON A, MAYHEW E,
MATTAY K, HUANG SK, WOODLE MC, LASIC DD, REDEMANN C
AND MARTIN FJ. (1991). Sterically stabilized liposomes:
improvements in pharmacokinetics and anti-tumor therapeutic
efficacy. Proc. Natl Acad. Sci. USA, 88, 11460- 11464.
PARK JG, FRUCHT H, LAROCCA RV, BLISS DPJ, KURITA Y, CHEN
TR, HENSLEE JG, TREPEL JB, JENSEN RT, JOHNSON BE, BANG
YJ, KIM JP AND GAZDAR AF. (1990). Characteristics ofcell lines
established from human gastric carcinoma. Cancer Res., 50,
2773 -2780.
PARK JW, STAGG R, LEWIS GD, CARTER P, MANEVAL D, SLAMON
DJ, JAFFE H AND SHEPARD HM. (1992). Advances in cellular and
molecular biology of breast cancer. In Genes, Oncogenes,
Hormones, Dickson RB and Lippman ME. (eds) pp. 193-211.
Kluwer Academic Publishing: Boston.
PARK JW, HONG K, CARTER P, ASGARI H, GUO LY, KELLER GA,
WIRTH C, SHALABY R, KOTTS C, WOOD WI, PAPAHADJOPOU-
LOS D AND BENTZ CC. (1995). Development of anti-pl85HER2
immunoliposomes for cancer therapy. Proc. Natl Acad. Sci. USA,
92, 1327-1331.
PEETERS PA, BRUNINK BG, ELING WM AND CROMMELIN DJ.
(1989). Therapeutic effect of chloroquine (CQ)-containing
immunoliposomes in rats infected with Plasmodium berghe:
parasitized mouse red blood cells: comparison with combination
of antibodies and CQ or liposomal CQ. Biochim. Biophys. Acta,
981, 269-276.
PRESS MF, CORDON-CARDO C AND SLAMON DJ. (1990).
Expression of the HER-2/neu proto-oncogene in normal human
adults and fetal tissues. Oncogene, 5, 953-962.
SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A AND
MCGUIRE WL. (1987). Human breast cancer: correlation of
relapse and survival with amplification of the HER-2 neu
oncogene. Science, 235, 177- 182.
SLAMON DJ, GODOLPHIN W, JONES LA, HOLT JA, WONG SG,
KEITH DE, LEVIN WJ, STUART SG, UDOVE J, ULLRICH A AND
PRESS MF. (1989). Studies of the HER-2/neu protooncogene in
human breast and ovarian cancer. Science, 244, 707- 712.
STANCOVSKI I, HURWITZ E, LEITNER 0, ULLRICH A, YARDEN Y
AND SELA M. (1991). Mechanistic aspects of the opposing effects
of monoclonal antibodies to the erbB-2 receptor on tumor
growth. Proc. Natl Acad. Sci. USA, 88, 8691-8695.
UZIELY B, JEFFERS S, ISACSON R, KUTSCH K, WEI-TSAO D,
YEHOSHUA Z, MUGGIA FM AND GABIZON A. (1995).
Liposomal doxorubicin: antitumor activity and unique toxicities
during two complementary phase I studies. J. Clin. Oncol., 13,
1777 - 1785.
VAAGE J, BARBERA-GUILLEM E, ABRA R, HUANG A AND
WORKING P. (1994). Tissue distribution and therapeutic effect
of intravenous free or encapsulated liposomal Doxorubicin on
human prostate carcinoma xenografts. Cancer, 73, 1478- 1484.
WILLIAMS SS, ALOSCO TR, MAYHEW E, LASIC DD, MARTIN FJ
AND BANKERT RB. (1993). Arrest of human lung tumor
xenograft growth in severe combined immunodeficient mice
using Doxorubicin encapsulated in sterically stabilized lipo-
somes. Cancer Res., 53, 3964- 3967.
YONEMURA Y, NINOMIYA I, YAMAGUCHI A, FUSHIDA S,
KIMURA H, OHOYAMA S, MIYAZAKI I, ENDOU Y, TANAKA M
AND SASAKI T. (1991). Evaluation ofimmunoreactivity for erbB2
protein as a marker ofpoor short term prognosis in gastric cancer.
Cancer Res., 51, 1034- 1038.
ZALIPSKY S. (1993a). Synthesis of an end-group functionalized
polyethylene glycol-lipid conjugate for preparation of polymer-
grafted liposomes. Bioconjug. Chem., 4, 296-299.
ZALIPSKY S, NEWMAN M, PUNTAMBEKAR B AND WOODLE MC.
(1993b). Model ligands linked to the polymer-chains on liposomal
surfaces: application of a new functionalized polyethylene
glycol-lipid conjugate. Polym. Mater. Sci. Eng., 67, 519-520.
ZALIPSKY S, PUNTAMBEKAR B, BOULIKAS P, ENGBERS CM AND
WOODLE MC. (I1995). Peptide attachment to extremities of
liposomal surface grafted PEG chains: preparation of the long-
circulating form of laminin pentapeptide, YIGSR. Bioconjugate
Chem., 6, 705 -708.